Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's DiseaseGlobeNewsWire · Oct 13, 2026
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease TranscriptSeeking Alpha · Oct 1, 2026
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease TrialBenzinga · Oct 1, 2026
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's DiseaseGlobeNewsWire · Oct 1, 2026
AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Average Target Price of $37.50Defense World · Sep 30, 2026
AgomAb Therapeutics: Building A New Treatment Layer In FibrosisSeeking Alpha · Sep 16, 2026AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials.